Pune's Bharti Vidyapeeth Medical College to begin phase 2 trials of Oxford COVID-19 vaccine from tomorrow
The institution, which is one of the 17 sites chosen by Serum Institute of India to conduct the trials, has been given a target of enlisting 300 to 350 volunteers
Pune: Doses of the potential coronavirus vaccine developed by researchers at Oxford University arrived at the Bharti Vidyapeeth's Medical College for phase 2 human trials on Tuesday, an official said.
The trial may begin from Wednesday, said a top official of the institute, one of the 17 sites selected for the phase 2 human trials in the country by Serum Institute of India (SII).
"To start with we have identified five volunteers who will undergo COVID-19 and antibodies test. Those whose reports are negative will be shortlisted for vaccination on Wednesday," said Dr Sanjay Lalwani, Medical Director, Bharti Vidyapeeth's Medical College and Hospital and Research Centre.
He said the hospital has been given a target of enlisting 300 to 350 volunteers. Those chosen for receiving a dose of vaccine will be in the age group of 18 to 99 years, he told PTI.
Dr Jeetendra Oswal, deputy medical director of the hospital, said after they are administered the vaccine, the volunteers will be monitored as per the standard trial protocol.
The other hospitals where trials are to be conducted include BJ Medical College Hospital in Pune, AIIMS Delhi, Rajendra Memorial Research Institute of Medical Sciences in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, Nehru Hospital in Gorakhpur and Andhra Medical College in Visakhapatnam.
SII, the world's largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company Astra Zeneca.
Centre and states should work as team to combat COVID pandemic, rise above politics, says PM Modi at all-party meet
A number of Opposition parties including the Trinamool Congress, NCP and Samajwadi Party attended the meet, while the main Opposition party Congress skipped it
COVID-19 vaccine production increasing, India may be first country to have DNA-based jab, Mansukh Mandaviya tells RS
Replying to a short discussion on COVID-19 management in Rajya Sabha, the minister said technology transfer to several companies has started and they will begin production in the coming days
The ICMR head, however, added a caveat that for such a step to be considered, it must be ensured that school teachers and other support staff members are vaccinated